Oncology Unit, Department of Clinical Therapeutics, Alexandra Hospital, Athens, Greece.
1st Department of Radiology, Aretaieio University hospital, Athens, Greece.
BMC Urol. 2020 Jun 2;20(1):60. doi: 10.1186/s12894-020-00618-1.
Kidney cancer is a lethal neoplasm that affects several thousands of people every year. Renal cell carcinoma (RCC) is the most common histologic type. Recent developments in the therapeutic approach include antiangiogenic targeted approaches and Immunotherapy. Thus, the therapeutic algorithm of RCC patients and the survival outcomes have changed dramatically.
Herein we present a retrospective study of the patients treated in our Department with an antiangiogenic agent -Axitinib, a tyrosine kinase inhibitor- as a third or further line treatment. Statistical analysis was performed with SPSS, including the available clinicopathological data of the patients included.
Axitinib was found to be active in patients who received this treatment beyond second line. The toxicity profile of this regimen did not reveal any unknown adverse events.
Our real world data reflect that axitinib is a safe and effective option, even beyond the second line.
肾癌是一种致命的肿瘤，每年影响数千人。肾细胞癌（RCC）是最常见的组织学类型。治疗方法的最新进展包括抗血管生成靶向治疗和免疫治疗。因此，RCC 患者的治疗方案和生存结果发生了巨大变化。
本文回顾性分析了在我院接受抗血管生成药物-阿昔替尼（一种酪氨酸激酶抑制剂）作为三线或以上治疗的患者。采用 SPSS 进行统计学分析，包括纳入患者的临床病理资料。
阿昔替尼在接受二线以上治疗的患者中显示出活性。该方案的毒性谱未显示任何未知的不良事件。
我们的真实世界数据表明，阿昔替尼是一种安全有效的选择，甚至可以超越二线治疗。
